Synthesis: Endpoint design (pCR, RCB, EFS, OS)

Evidence grades (GRADE-adapted): A high — multiple well-conducted RCTs or systematic reviews converge. B moderate — single pivotal RCT or consistent observational evidence. C limited — single observational study, mechanistic, or expert consensus. D preclinical / hypothesis-generating.

The endpoint hierarchy

Clinical trials require endpoints that are measurable, clinically meaningful, and feasible within the trial's time horizon. In early-stage TNBC, the endpoint trade-off is between speed of readout (shorter is faster) and clinical relevance (long-term outcomes matter most to patients). The endpoints used in TNBC trials, roughly ordered by readout speed:

• pCR — pathologic complete response at surgery, measurable within months of trial initiation
• RCB — residual cancer burden, continuous measure at surgery
• EFS — event-free survival, capturing any disease event (recurrence, contralateral cancer, death). Typically 3–5 year primary readouts.
• iDFS — invasive disease-free survival, narrower than EFS (excludes some non-invasive events). 3–5 year readouts.
• DDFS — distant disease-free survival, focusing on distant recurrence. 3–5 year readouts.
• OS — overall survival, the ultimate efficacy endpoint. Typically 5–10 year readouts.

In metastatic TNBC trials, the principal endpoints are:

• ORR — objective response rate, measurable within months
• PFS — progression-free survival, typically 6–12 month median readouts
• OS — overall survival, typically 12–24 month median readouts

pCR — the most-debated endpoint

See the pCR as endpoint synthesis for detailed coverage. Key points:

• Patient-level prognosis association: very strong in TNBC (EFS HR 0.24 from CTNeoBC)
• Trial-level surrogacy: weaker (R² ~0.30 in CTNeoBC trial-level regression)
• Regulatory: FDA-approved as accelerated-approval endpoint for high-risk early-stage breast cancer (2014 guidance, confirmed via KEYNOTE-522)

RCB — continuous granular measure

Residual cancer burden (Symmans 2007 / 2017) provides finer granularity than the pCR / no-pCR dichotomy^[1]A. RCB-I (minimal residual disease) has prognosis similar to pCR; RCB-III has substantially worse prognosis. RCB-II is intermediate.

Advantages: captures dose-response information that pCR loses; enables better risk stratification of "no-pCR" patients. Limitations: requires specific pathologic methodology not universally implemented; reporting standardization varies across centers.

Event-time endpoints — EFS, iDFS, DDFS, OS

EFS (event-free survival)

EFS captures the time from randomization (or treatment initiation) until any event: invasive recurrence (local, regional, distant, or contralateral), second primary breast cancer, or death from any cause. Used as a primary endpoint in KEYNOTE-522 and many neoadjuvant-trial designs. EFS captures more events than iDFS or DDFS and therefore reaches statistical power faster.

iDFS (invasive disease-free survival)

iDFS captures invasive recurrence (local, regional, distant, or contralateral invasive cancer) and death. Excludes non-invasive (DCIS) recurrence and second non-breast primaries. Used as the primary endpoint in OlympiA and several other recent adjuvant trials. Better aligned to the question of whether the treatment prevents the invasive disease that drives mortality.

DDFS (distant disease-free survival)

DDFS captures distant recurrence and death. Excludes local-regional recurrence, which is presumed to be addressed by local therapy rather than systemic. Used as a primary or secondary endpoint in some trials.

OS (overall survival)

OS is the most patient-meaningful endpoint and the ultimate efficacy standard. In TNBC adjuvant trials, OS requires long follow-up (5–10 years) because mortality events accumulate slowly relative to recurrence events. Adjuvant trials are increasingly designed with iDFS or EFS as primary endpoints and OS as the long-term confirmatory endpoint.

Surrogate-endpoint debate

Surrogate endpoints are early-readout endpoints used to predict later, more meaningful endpoints. The question of surrogacy is whether changes in the surrogate reliably predict changes in the true outcome:

• Patient-level surrogacy: within a single trial, do patients who hit the surrogate endpoint have different long-term outcomes than those who don't? For pCR in TNBC, yes (CTNeoBC analysis).
• Trial-level surrogacy: does a treatment that improves the surrogate reliably also improve the long-term endpoint? For pCR in TNBC, partially — the CTNeoBC trial-level R² is modest.

Failed examples (treatments that improved pCR but not OS) include bevacizumab in HER2-positive breast cancer and some PARP inhibitor combination strategies. Successful examples include KEYNOTE-522 (positive pCR followed by positive EFS).

The FDA's accelerated-approval framework accepts pCR as evidentiary basis for accelerated approval contingent on confirmatory event-time data, balancing the speed of pCR-based approval with the requirement for long-term confirmation.

Emerging ctDNA-based endpoints

Circulating tumor DNA detection after neoadjuvant therapy or after definitive treatment provides a non-tissue measure of minimal residual disease (MRD). ctDNA-positive status post-treatment correlates with substantially higher recurrence risk than ctDNA-negative status^[2]B. Several ctDNA-based endpoint concepts:

• MRD-positive at fixed timepoint — rate of ctDNA-positive patients at specified time after treatment
• MRD-clearance rate — rate of conversion from ctDNA-positive to ctDNA-negative under additional treatment
• Time to MRD-positivity — time from treatment completion until first ctDNA-positive sample
• Combined surrogate — pCR + ctDNA-negative status as a composite

Whether ctDNA-based endpoints can support accelerated approval analogous to pCR is being explored. The technical and analytical standardization challenges (which ctDNA assay? what threshold? what timepoint?) are substantial but progressing.

Composite and patient-centered endpoints

Beyond the standard efficacy endpoints, additional considerations:

• Quality-adjusted survival — integrating survival duration with quality-of-life metrics
• Patient-reported outcomes — symptom burden, treatment tolerability (see PRO synthesis when available)
• Net clinical benefit — balancing efficacy gains against toxicity costs
• Health-economic outcomes — cost-effectiveness ratios for payer decisions

These broader endpoints are increasingly required for full regulatory and reimbursement evaluation of new TNBC therapies.

Evidence table

Open questions and active investigation

• ctDNA endpoints in regulatory submissions. Will the FDA accept ctDNA MRD-clearance as a basis for accelerated approval analogous to pCR? Several drug-development programs are positioning toward this outcome.
• RCB-based endpoint standardization. If RCB-I is functionally equivalent to pCR for prognosis, trials should ideally use RCB-based composite endpoints rather than the dichotomous pCR / not-pCR split. Adoption is increasing but not universal.
• Combined biomarker-and-pathology endpoints. Composite endpoints integrating pCR, RCB, ctDNA, and clinical features may have better surrogacy properties than any single component.
• Patient-meaningful endpoints in metastatic trials. Beyond PFS and OS, capturing quality-of-life and symptom-burden improvements would better reflect patient priorities. Standardized PRO measurement and integration into primary endpoints is being explored.
• Surrogate endpoint evaluation methodology. Better statistical frameworks for evaluating surrogacy at the trial level would inform which surrogate endpoints can support regulatory decisions.
• Early-stage TNBC OS data maturation. KEYNOTE-522 OS data will mature over the next 5 years; whether OS confirms the EFS benefit will reinforce or weaken the pCR-EFS-OS surrogacy chain.

For pCR specifically, see the pCR as endpoint synthesis. For trial designs that use these endpoints, see the (forthcoming) adaptive platform trials synthesis and the biomarker-stratified design synthesis.

References

Each citation links to the original publication via DOI. The same records are searchable in the evidence library by title or DOI.

1. Symmans WF, Wei C, Gould R, et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden Classification. J Clin Oncol. 2017;35(10):1049–1060. doi:10.1200/JCO.2015.63.1010. ↩
2. Magbanua MJM, Swigart LB, Wu HT, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229–239. doi:10.1016/j.annonc.2020.11.007. ↩
3. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172. doi:10.1016/S0140-6736(13)62422-8. ↩

Last reviewed: 2026-06-04. Researcher-layer synthesis page. Evidence grades follow the GRADE-adapted rubric defined at the top of this page.